Last reviewed · How we verify
CISATRACURIUM BESYLATE
Cisatracurium besylate blocks neuromuscular transmission by competitively binding to cholinergic receptors and antagonizing acetylcholine.
Cisatracurium besylate is a marketed neuromuscular blocking agent primarily used for facilitating tracheal intubation. Its key strength lies in its mechanism of action, which effectively blocks neuromuscular transmission by competitively binding to cholinergic receptors and antagonizing acetylcholine. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | CISATRACURIUM BESYLATE |
|---|---|
| Target | cholinergic receptors |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1995 |
Mechanism of action
Cisatracurium besylate works by binding to cholinergic receptors at the motor end-plate, which prevents acetylcholine from binding and transmitting signals between nerves and muscles. This results in muscle relaxation. The effect can be reversed by drugs like neostigmine, which inhibit acetylcholinesterase.
Approved indications
- Tracheal Intubation Facilitation
- Skeletal Muscle Relaxation During Surgery
- Skeletal Muscle Relaxation During Mechanical Ventilation
- Skeletal Muscle Relaxation During Pediatric Surgery
Common side effects
- Bradycardia
- Hypotension
- Flushing
- Bronchospasm
- Rash
Drug interactions
- Succinylcholine
- Inhalational Anesthetics
- Antibiotics
- Local Anesthetics
- Magnesium Salts
- Procainamide
- Lithium
- Quinidine
- Phenytoin
- Carbamazepine
Key clinical trials
- Propofol Versus Sevoflurane Anesthesia on the Intraocular Pressure and Hemodynamics in Patient Undergoing Cyclophotocoagulation (NA)
- Safety and Efficacy of HRS-9190 Compared to Cisatracurium for Continuous Intravenous Infusion in Adults (PHASE2)
- Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease (PHASE4)
- Continuous Versus 1-min Oscillometric Arterial BP Monitoring (NA)
- Tubeless Spontaneous Ventilation Anesthesia in Kidney Transplantation (NA)
- Partial Neuromuscular Blockade in Acute Hypoxemic Respiratory Failure (NA)
- Differences in Speed of Recovery From Anesthesia for Intraoral Surgery (NA)
- Comparison for the Effect of Neuromuscular Blocking Agents Versus Sedation Alone on Severe ARDS Patients Due to COVID-19 (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CISATRACURIUM BESYLATE CI brief — competitive landscape report
- CISATRACURIUM BESYLATE updates RSS · CI watch RSS